CDH2 and cancer: It is well documented that upregulation of N-cadherin, a mesenchymal marker in epithelial–mesenchymal transition (EMT), and repression of E-cadherin, an epithelial marker, promote migratory phenotype and invasiveness of cancer cells [17,18,19].